To note that the selective activation of ERβ could be of clinical value since it does not induce the classic side effects, mediated by ERα, observed after estrogen administration (e.g., cerebro- and cardiovascular events, higher occurrence of endometrial and breast cancer). Here, ESR2 is linked to breast cancer.